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ABSTRACT
ALI (acute lung injury) and its more severe form ARDS (acute respiratory distress syndrome)
are inﬂammatory diseases of the lung characterized by hypoxaemia and diffuse bilateral inﬁltrates.
Disruption of epithelial integrity and injury to endothelium are contributing factors of the deve-
lopment of ALI/ARDS, and alveolar damage is the most pronounced feature of ALI/ARDS. The
resulting increase in lung microvascular permeability promotes inﬂux of inﬂammatory cells to the
alveolar spaces. Oedema ﬂuid contains pro-nﬂammatory mediators and plasma proteins, including
Igs (immunoglobulins). Moreover, several reports describe the presence of autoantibodies and
immune complexes [anti-IL-8 (interleukin-8) autoantibody/IL-8 complexes] in lung ﬂuids (oedema
and bronchoalveolar lavage ﬂuids) from patients with ALI/ARDS. These immune complexes
associate with FcγRIIa (Fcγ IIa receptor) in lungs of patients with ARDS. Furthermore, the
expression of FcγRIIa is substantially elevated in lungs of these patients. FcγRIIa appears on
virtually all myeloid cells, platelets and endothelial cells. It is a low-afﬁnity receptor for IgG
that preferentially binds aggregated immunoglobulins and immune complexes. FcγRs regulate
phagocytosis and cell-mediated cytotoxicity, and initiate the release of inﬂammatory mediators. It
should be noted that immune complexes formed between either anti-neutrophil autoantibodies
and their speciﬁc antigens or anti-HLA (human leucocyte antigen) antibodies and target antigens
areimplicatedinthepathogenesisofTRALI(transfusion-relatedacutelunginjury),andimportantly,
animal studies indicate that FcγRs are essential for these complexes to cause damage to the lungs.
Therefore, we hypothesize that FcγRs such as FcγRIIa could contribute to the pathogenesis of
ALI/ARDS.
ALI (ACUTE LUNG INJURY)/ARDS (ACUTE
RESPIRATORY DISTRESS SYNDROME)
ALI and the ARDS were ﬁrst described in 1967
and represent a severe form of diffuse lung disease.
Alternations of lung function in these pathological
entities include rapid onset of dyspnoea, hypoxaemia
and respiratory failure. The alveolar-capillary barrier be-
comes disrupted allowing massive inﬂux of oedema ﬂuid
and inﬂammatory cells. The formation of pulmonary
oedema is a consequence of both endothelial injury and
increased vascular permeability. In accordance with the
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recommendationsoftheAmerican–EuropeanConsensus
Conference Committee (the consensus deﬁnition of
1994), patients are classiﬁed as having ALI when charac-
teristic changes in lung compliance and residual capacity
of the lungs are found. Diagnosis of ALI is given when
an individual rapidly (in less than 7 days) develops severe
hypoxaemia[aratioofthepartialpressureofarterialoxy-
gen to the fraction of inspired oxygen (Pao2/Fio2) is 300
orless],andthefrontalradiographisabnormal(visiblein-
ﬁltrate).Infact,thepresenceofdiffusebilateralinﬁltrates
onchestradiographisindicativeofpulmonaryoedemain
patients with ALI. More severe hypoxaemia (Pao2/Fio2
of 200 or less) warrants diagnosis of ARDS [1–4].
Clinical disorders associated with the progression to
ALI/ARDS can be divided into two groups, i.e. diseases
directly affecting the lungs such as pneumonia or gastric
aspiration and conditions that can indirectly lead to lung
injury such as sepsis or severe trauma [1,3]. Signiﬁcantly,
the highest risk of developing ALI/ARDS is attributed
to sepsis [1,4]. There are also additional factors that can
predispose individuals for development of ALI/ARDS,
as for example, alcoholism or polymorphism of certain
genes [1,3]. Nevertheless, the disease course is similar
between pulmonary and extrapulmonary ALI/ARDS
[3].
INCIDENCE OF AND THERAPY FOR ALI/ARDS
The incidence of ALI and ARDS in the United States
is 79 cases and 59 cases per 100000 persons per year
respectively. Because of lack of effective treatment
modalitiesforALI/ARDS,themortalityremainsatabout
40% [1,4].
TherapiesavailableforALI/ARDSarenonspeciﬁcand
generally supportive, including mechanical ventilation
[1–3]. Since hyperactive inﬂammation is one well-
recognized feature of ALI/ARDS [5,6] (see below),
several trials of steroid effectiveness in patients with
ALI/ARDS have been conducted. Prolonged treatment
with low doses of corticosteroids has been shown to
improve both lung function and survival of patients
with ALI/ARDS [7]. These ﬁndings are consistent with
a causal role for the host inﬂammatory response in
the early stages of the disease that ultimately drives
activation of the coagulation cascade and inhibition of
ﬁbrinolysis.However,therapiestorestorehomeostasisin
thecoagulationorﬁbrinolyticsystemsareeitherpartially
effective or not effective at all and are associated with
serious complications [8,9].
PATHOBIOLOGY OF ALI/ARDS
Early stage of ALI/ARDS (exudative phase) is associated
with diffuse alveolar damage, neutrophil inﬁltrate,
haemorrhage and the accumulation of a protein-rich
pulmonary oedema (Figure 1). Other histopathological
changes that are characteristic of the exudative phase in-
clude disruption of the epithelial barrier and injury to the
capillary endothelium. Some patients with ALI/ARDS
progress to a ﬁbroproliferative phase, during which
chronic inﬂammation, ﬁbrosis and neovascularization
take place. The ﬁnal stage of ALI/ARDS, in surviving
patients, is the recovery phase that results in a variable
degree of restoration of lung function in these patients
[1–3]. During the exudative phase, cytokines and other
pro-nﬂammatory molecules initiate, amplify and per-
petuate inﬂammatory responses in the lungs. Increased
oxidative stress and the appearance of proteolytic
enzymes in the alveolar spaces and interstitium results in
a substantial decrease in the surfactant level in the lungs
and thereby promotes atelectasis. Elastolytic proteases
disrupt the structural framework of the lung. In addition,
damagetotheepithelialbarriercontributestoandexacer-
bates the alveolar ﬂooding, and also delays recovery by
impairing ﬂuid clearance. Finally, capillary thrombosis
is most probably brought about by an impairment
in the balance between pro-/anti-coagulant and pro-/
anti-ﬁbrinolytic proteins [2,3].
The increase in lung microvascular permeability
and the resultant formation of pulmonary oedema
are causative of alveolar ﬂooding. Lung ﬂuids from
patients with ALI/ARDS contain an abundance of
plasma proteins and inﬂammatory mediators. Studies
from several laboratories have described the presence
of various autoantibodies in these ﬂuids [10–13]. Our
ﬁndings indicate that autoantibodies directed against
IL-8 (interleukin-8) form immune complexes (anti-IL-
8 autoantibody/IL-8 immune complexes) in lung ﬂuids
from patients with ALI/ARDS [10,11]. Furthermore,
anti-IL-8 autoantibody/IL-8 immune complexes are
found in association with FcγRIIa (Fcγ receptor IIa) in
pulmonary tissues from these patients [14].
IgG/IMMUNE COMPLEX RECEPTORS (FcγRs)
FcγRs interact with the Fc portion of IgG. To date,
three different classes of FcγRs have been identiﬁed in
humans, i.e. FcγRI, FcγRII and FcγRIII. The FcγRI
family contains four different isoforms (Ia, Ib1, Ib2 and
Ic), the FcγRII group comprises six proteins (IIa1, IIa2,
IIb1,IIb2,IIb3andIIc),andtheFcγRIIIgrouptwo(IIIa
and IIIb). FcγR sc o n s i s to ft w o( F c γRII and FcγRIII) or
three(FcγRI)N-terminalextracellularimmunoglobulin-
like domains (ligand binding domains), a transmembrane
region and an intracellular tail with a C terminus.
FcγRIexhibitshighafﬁnityformonomericIgG,whereas
FcγRII and FcγRIII bind immune complexes more
efﬁciently than uncomplexed IgG. The binding afﬁnities
of FcγRs are inﬂuenced additionally by variations in
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Figure 1 Events characterizing early stage of lung damage in patients with ALI/ARDS
See text for details.
glycosylation patterns of both the receptors and IgG
[15,16].
DIVERSE FUNCTIONS OF FcγRs
Functionally, FcγRs can be divided into two categories:
activating and inhibitory receptors. Activating FcγRs
contain ITAM (immunoreceptor tyrosine-based activ-
ation motif), while inhibitory FcγRs contain ITIM
(immunoreceptor tyrosine-based inhibitory motif).
Cross-linking of the former receptors is followed by
phosphorylation of tyrosine residues within the ITAM
by kinases of the Src [v-src sarcoma (Schmidt-Ruppin A-
2)viraloncogenehomologue]family.Thisinturninitiates
the FcγR signalling cascade [15,16] (Figure 2).
ITAM-bearing FcγRs mediate a pleiotropy of
functions in various cell types. These functions include
facilitating phagocytosis of diverse pathogens, induction
of antibody dependent cytotoxicity, modulation of cell
activation, regulation of apoptosis and triggering of the
release of pro-inﬂammatory mediators [15,16].
FcγRIIb, an ITIM-containing receptor, is the only
inhibitory FcγR. It is expressed on B cells, mast cells,
macrophages, monocytes and neutrophils, and inhibits
pro-inﬂammatory functions of these cells [15,16].
POLYMORPHISM OF FcγRs
Two allelic forms of FcγRIIa have been described in
humans: FcγRIIa-R131 and FcγRIIa-H131. FcγRIIa-
R131 has an arginine (R) residue, while FcγRIIa-H131
has a histidine (H) residue at position 131. The ﬁrst
allotype binds all human IgG subclasses, particularly
IgG2, with low afﬁnity, whereas the second one binds
IgG2 and IgG3 with higher afﬁnity. Only one variant
of the FcγRIIb gene exists, in which isoleucine (I) at
position 232 is replaced by a threonine (T) residue.
FcγRIIb-T232 displays enhanced ability to inhibit
B-cell receptor signalling compared with FcγRIIb-I232
[15].
FcγRIIIa was shown to have two allelic forms, i.e.
FcγRIIIa-V158,whichhasavaline(V)residueatposition
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Figure 2 FcγRIIa signalling cascade
Activation of the Src kinases leads to the recruitment of a kinase from the
Syk family followed by phosphorylation of a series of downstream proteins
such as phosphoinositide 3-kinase (PI3-K). Subsequent events include production
of PtdIns(3,4,5)P3 and recruitment of Bruton’s tyrosine kinase (BtK) and
phospholipase Cγ (PLCγ). This leads to increased calcium mobilization and also
triggers additional downstream signalling events as activation of the Ras/Raf/MAPK
(mitogen-activated protein kinase) pathways [15,16]. DAG, diacylglycerol; ERK,
extracellular-signal-regulated kinase; InsP3, Ins(1,4,5)P3; JNK, c-Jun N-terminal
kinase; PKC, protein kinase C.
158, and FcγRIIIa-F158 that has a phenylalanine (F)
residue in that position. The former allelic variant of
FcγRIIIa binds IgG1,I g G 3 and IgG4 with higher afﬁnity
than the FcγRIIIa-F158 variant. Three alleles of the
FcγRIIIb gene are known (NA1, NA2 and SH). The
NA1 type mediates phagocytosis of IgG1-a n dI g G 3-
opsonizedparticlesmoreefﬁcientlythantheNA2variant
[15].
PolymorphismsinFcγRgenesinﬂuencesusceptibility
of individuals to the development of many autoimmune
diseasesandtoacquiringofvariousinfections.Patientre-
sponses to treatment with intravenous immunoglobulins
and monoclonal antibodies are also affected [15].
HYPOTHESIS: FcγRs IN ALI/ARDS
Our hypothesis is that immune and inﬂammatory
responses triggered in the host during the development
of ALI/ARDS lead to an increase in expression and
functionality of FcγRs, speciﬁcally FcγRIIa, in the lung.
In support of this hypothesis, we have shown that the
level of FcγRIIa is higher in lung tissues from patients
with ARDS than in normal lung tissues [14] (Figure 3).
Moreover, Hietbrink et al. [17] and Kanters et al. [18]
reported that lung ﬂuid neutrophils from three patients
with ALI were in a highly primed state characterized by
elevated expression of an epitope that the authors later
classiﬁed as ‘activated’ FcγRIIa.
Additional indirect supportive data for our hypothesis
comes from two recently published studies [19,20]. In
the ﬁrst one, Endeman et al. described the presence of
the association between the FcγRIIa-R131 genotype and
severe sepsis in community-acquired pneumonia [19].
The authors of the second manuscript summarized the
results of multiple clinical trials of patients with sepsis,
severe sepsis or septic shock who received polyclonal
intravenous immunoglobulin therapy. They concluded
thattherewasasurvivalbeneﬁtofthistherapyinpatients
with sepsis [20]. This ﬁnding indicates that FcγRs could
contribute to the pathogenesis of sepsis (see below),
which constitutes the major risk factor for development
of ALI/ARDS [1,4].
LIGANDS FOR FcγRs IN PATIENTS WITH
ALI/ARDS
A considerable subpopulation of FcγRIIa in lungs
of patients with ALI/ARDS associate with anti-IL-
8 autoantibody/IL-8 immune complexes [14,21]. At
present, it is not known what the pathophysiological
signiﬁcance of this observation is. However, our group
reported that anti-IL-8 autoantibody/IL-8 immune
complexes in lung ﬂuids from patients with ALI/ARDS
are important prognostic indicators for the development
andultimateoutcomeofALI/ARDS[10,11,22].Presence
ofelevatedconcentrationsofthesecomplexeswasassoci-
atedwithpooroutcomeinpatientswithALI/ARDS[11].
We also detected anti-IL-8/IL-8 complexes (at increased
levels) in lung ﬂuids of patients at risk of ALI/ARDS
who later developed ALI/ARDS. These patients were
evaluated immediately after admission to intensive care
before inﬂux of neutrophils and lung injury occurred,
indicating that the complexes are formed locally in the
lung prior to the development of ALI/ARDS [22].
We have puriﬁed anti-IL-8 autoantibodies from lung
ﬂuids of ALI/ARDS patients. These autoantibodies bind
IL-8 with high afﬁnity (about 10−12 M) and inhibit the
activity of IL-8 in vitro when experiments are performed
using a mixture of IL-8 and autoantibodies (in excess)
[10]. However, complexes between these antibodies
and IL-8 puriﬁed from lung ﬂuids of ALI/ARDS
patients display pro-inﬂammatory activity via FcγRIIa
[21,23-25]. Moreover, blocking of FcγRIIa suppresses
the biological effects of these complexes in vitro
[21,23-25].
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Figure 3 Expression of FcγRIIa and association of IL-8 in anti-IL-8 autoantibody/IL-8 immune complexes with FcγRIIa in
normal lung tissues and tissues from ARDS patients
Left panels from the top: FcγRIIa (green)/IL-8 (red) x60. Big left panel: co-localization (yellow) of FcγRIIa (green) and IL-8 (red). Nuclei are stained blue. Right
panels from the top: FcγRIIa (green)/IL-8 (red) ×60. Big right panel: co-localization (yellow) of FcγRIIa (green) and IL-8 (red). Nuclei are stained blue. Acquisition
settings for the images were UV/567/647, and speciﬁc parameters for the ﬂuorophores were Cy3 (red) excitation at 567 nm and emission at 600 nm, Alexa 647
(pseudo-colour green) excitation at 647 nm and emission at 700 nm. The sections were evaluated using a PerkinElmer Ultra VIEW LCI confocal imaging system with a
Nikon TE2000-S ﬂuorescence microscope and a PlanApo’60 immersion oil objective. Ultra VIEW Imaging Suite software (version 5.5.0.4) was used for image processing.
Our studies were the ﬁrst to show that puriﬁed
anti-IL-8 autoantibody/IL-8 immune complexes trigger
chemotaxis of human blood neutrophils, induce
neutrophilactivationandmodulatesurvivalofthesecells.
Anti-IL-8/IL-8complexesalsohavetheabilitytodamage
human epithelial cells, promoting cell dysfunction and
loss of integrity. Moreover, these complexes display pro-
inﬂammatory activity towards human endothelial cells.
Finally, FcγRIIa are the principal receptors that mediate
the biological activities of the anti-IL-8/IL-8 complexes
in vitro [21,23-25].
Although whether anti-IL-8/IL-8 complexes are
causative of disease progression in vivo remains to be
established, autoantibodies/immune complexes can trig-
ger the development of ALI/ARDS in humans. Patients
with the ‘catastrophic’ variant of the antiphospholipid
syndrome can succumb to ALI/ARDS as do patients
receivingbloodtransfusions.TRALI(transfusion-related
acute lung injury) is believed to be a result of stimulatory
activity of immune complexes formed between either
anti-neutrophilautoantibodies andtheirspeciﬁcantigens
or anti-HLA (human leucocyte antigen) antibodies and
target antigens [26-28]. In addition, animal studies
indicate that FcγRs are essential for the latter complexes
to cause damage to the lungs [29].
ADDITIONAL EVIDENCE: ANIMAL MODELS
OF LUNG INJURY AND FcγRs
There is a substantial body of literature describing
regulation of lung inﬂammation in animal models
of immune complex-induced lung injury. Most of
these models rely on the reverse passive Arthus
reaction, a localized alveolitis triggered by deposition of
heterologous immune complexes. The local formation
of heterologous immune complexes is achieved by
intratracheal administration of IgG antibody against
a foreign antigen, such as BSA, followed by the
intravenous injection of this antigen [30]. We have
developed a mouse model of ALI triggered by anti-
KC(keratinocyte-derivedchemokine)autoantibody/KC
immune complexes and concluded that these complexes
are injurious for lungs based on our investigations in
mice [31]. Murine KC (CXCL1/KC) is a functional
homologue of IL-8 [32], so this model provides excellent
means for studying the mode of action of immune
complexescontainingautoantibodiestochemokines[31].
OthermurineCXCchemokinesthatpromoteneutrophil
migration include MIP-2 (macrophage inﬂammatory
protein 2) (CXCL2), LIX (lipopolysaccharide-induced
CXC chemokine) (CXCL5) and lungkine (CXCL15)
[33–35]. KC, however, shares more common properties
with human IL-8 than MIP-2, LIX or lungkine. KC is
an early response chemokine and is responsible for the
initial inﬂux of neutrophils to the alveolar compartment
[36]. Since platelet–neutrophil interactions have been
shown to contribute to lung injury in murine models
of acid-induced ALI, sepsis-associated ALI and TRALI,
and since FcγRIIa is expressed by both platelets and
neutrophils, it is very likely that this receptor facilitates
neutrophil capture by circulating platelets [15,16,37,38].
Furthermore, mice deﬁcient in all FcγRs or FcγRI
are protected from lung injury [30,31,39]. Importantly,
the same holds true for mice lacking FcγRIII, a murine
homologue of human FcγRIIa [16,30,39].
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Perhaps even more relevant are ﬁndings of atten-
uated inﬂammatory response in the lungs of LPS
(lipopolysaccharide)-treated mice or rats in the absence
of FcγRs [31,40]. Moreover, studies from our laboratory
as well as those of others indicate that there is cross-
talk between FcγRs, including FcγRIIa and TLR4 (toll-
like receptor 4) in human neutrophils [41] and in mouse
models of LPS-induced lung injury [42,43]. Finally,
there are reports suggesting a regulatory role of FcγRs
in Escherichia coli sepsis and Pseudomonas aeruginosa
pneumonia in mice [44,45].
It should be noted that anti-IL-8/IL-8 complexes
consist of one IgG and one IL-8 molecule [10] and are
capable of triggering complement activation (A. Krupa
and A.K. Kurdowska, unpublished work). However,
our in vitro experiments are performed in the absence
of serum or other sources of complement, and in
such conditions, complement activation cannot occur.
This is different from the situation in vivo where
complement activation plays an important role. It
has been demonstrated, for example, that blocking
of complement activation protects against lung injury
triggered by the administration of heterologous immune
complexes. Furthermore, C5a mediates activity of
immune complexes by regulating expression of FcγRs
[30,39]. Therefore, both complement and the FcγR
cascade are likely to be involved in orchestrating the
inﬂammatory events in ALI/ARDS.
TESTING OF THE HYPOTHESIS
The published data supporting our hypothesis is primar-
ily indirect evidence (‘by association’), predominantly
from in vitro studies and animal models of ALI. Despite
the inquisitory value of this observation, more studies
utilizing specimens from patients with ALI/ARDS are
certainly needed. Lung tissues from these patients should
be rigorously analysed for the presence of different
types of FcγRs. The levels and expression patterns of
FcγRsshouldalsobeevaluated.Ourstudies,forexample,
indicate that FcγRIIa is expressed in injured lungs and
is present on endothelial cells in patients with ARDS
[14,21]. Inﬂammatory cells in lung ﬂuids of patients
with ALI/ARDS should be similarly tested. Moreover,
it would be useful to know which proteins from the
FcγRIIa-signalling cascade are up- or down-regulated in
the lungs of these patients. Whether FcγRIIa is the only
or the most abundant FcγR in lungs in ALI/ARDS is at
present not known. Because of the limited availability
of clinical samples, ﬂuorescence-based methods, such
as laser confocal microscopy or ﬂuorescence resonance
energy transfer, are preferable.
Studies using well-established animal models of
ALI/ARDS and mice transgenic for FcγRIIa would
also be very valuable. Such mice have been generated
by other investigators [46,47]. When considering a
model of ALI/ARDS, one should take into account
the complexity of the disease in ALI/ARDS. Therefore,
two hit models are probably the most appropriate
[48]. Nevertheless, to study the role of FcγRIIa in
the pathogenesis of ALI/ARDS, a model of immune-
complex-triggered lung injury should be used initially
[30,31,39], then, perhaps treatment with LPS could be
added to create a two-hit model [31,40]. Contribution of
human autoantibodies/immune complexes such as anti-
IL-8/IL-8 complexes to the pathogenesis of lung injury
could also be studied using FcγR-deﬁcient mice that are
transgenic for FcγRIIa. These mice should be treated
with the immune complexes formed between IL-8 and
fully human anti-IL-8 monoclonal antibodies [49]. To
studytheroleofFcγRIIaindifferentpopulationsofcells,
adaptive transfer experiments could be performed. Cells
from mice lacking murine FcγRs and expressing human
FcγRIIa could be injected into FcγR-knockout mice
[47]. In addition, other common models of ALI/ARDS,
including ventilator-induced lung injury and hyperoxia,
ought to be evaluated using mice deﬁcient in FcγRs
that are transgenic for human FcγRIIa [48]. Moreover,
FcγRIIa may be inhibited in the above-described mouse
models employing speciﬁc FcγRIIa blockers [50–52].
Finally, the role of FcγR signalling could be explored
in these models taking advantage of the availability of
smallinhibitorsofsignallingproteinsandsilencingRNAs
targeting these proteins [53–55].
CONCLUSIONS
Studies with animal models of ALI/ARDS and FcγRIII
(homologue of human FcγRIIa)-deﬁcient mice support
our hypothesis [30,31,39,40,43–45]. Our ﬁndings of
increased levels of FcγRIIa and its association with
anti-IL-8/IL-8 immune complexes in lungs of patients
with ARDS provide direct evidence of expression of
functional FcγRIIa in the lungs of these patients [14,21].
The relevance of these observations is substantiated by
the several facts described by us and other researchers.
First of all, concentrations of anti-IL-8/IL-8 immune
complexes in lung ﬂuids from patients with ALI/ARDS
were predictive of disease progression and the eventual
outcome of ALI/ARDS [10,11,22]. Secondly, puriﬁed
complexes exhibit pro-inﬂammatory activities in vitro
[21,23-25]. Thirdly, other autoantibodies have been
detected in patients with ALI/ARDS, and also could
be correlated with disease activity [12,13]. Finally,
autoantibodies/immune complexes at large are known to
induce ALI/ARDS in humans [26–28].
At present, involvement of FcγRIIa in the patho-
physiology of ALI/ARDS is not understood, but the
many basic and clinical studies place this receptor
at the ‘heart’ of the inﬂammatory milieu in the
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lung. It is certainly conceivable that FcγRIIa could
contribute to the pathogenesis of ALI/ARDS. Keeping
in mind the association of FcγRIIa polymorphism with
the development of sepsis (a major risk factor for
ALI/ARDS) in community-acquired pneumonia, one
can envision that this receptor could play an important
regulatoryroleduringthecourseofthisillness,asevident
from animal models of sepsis and pneumonia [19,44,45].
Comprehensive research into the function and
molecular mechanisms of FcγRIIa activity could lead
to development of novel and more effective therapies
for ALI/ARDS. It is important to note that speciﬁc
inhibitory molecules, i.e. FcγRIIa blockers, have already
been tested in animal models of inﬂammation [50–52].
Signalling proteins from the FcγRIIa cascade could serve
as therapeutic targets as well. The progress made in
the ﬁelds of designing and utilizing small inhibitors of
signalling proteins and pulmonary delivery of inhibitory
entities makes this possibility very attractive [53–55].
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